pharma · TTR-mediated Amyloidosis · Hypertension · ALNY
Alnylam Netherlands
Alnylam Netherlands B.V.
Alnylam Netherlands is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker ALNY. Primary therapeutic focus areas include TTR-mediated Amyloidosis, Hypertension, Transthyretin Amyloidosis
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2002
- Employees
- 2,826
- Programs
- 84
- Drugs
- 37
- Patents
- 379
A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease
Phase 1 · other · Huntington’s disease
A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease for Huntington’s disease is a Phase 1 program (other) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code ALN-HTT02-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Alnylam Netherlands B.V.
- Phase
- Phase 1
- Modality
- other
- Indication
- Huntington’s disease
- Status
- active
- Trials
- 1